GILD Gilead Sciences Inc.

82.29
-0.68  -1%
Previous Close 82.97
Open 83.39
Price To book 4.74
Market Cap 107464668397
Shares 1,305,926,217
Volume 6,069,697
Short Ratio 1.79
Av. Daily Volume 9,736,551

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Filgotinib
Ulcerative Colitis
Phase 3 ongoing.
Filgotinib
Crohn's Disease
Phase 3 ongoing.
Filgotinib
Rheumatoid Arthritis
Phase 3 futility analysis 3Q 2017.
GS-5745
Gastric Cancer
Phase 3 trial initiated.
F/TAF
Pre exposure prophylaxis
PDUFA date under priority review February 12, 2018.
Bictegravir/F/TAF
HIV
Phase 3 planned.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 3 planned.
Selonsertib (GS-4997)
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 4Q 2017.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 2 trial to be completed 3Q 2017.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Phase 3 planned.
Entospletinib
Acute Myeloid Leukemia
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)